• Poster

Impact Of The FDA Draft Guidance on Patient Reported Outcomes (PRO) Label Claims for Approved Drug Products in the US: Has It Made a Difference?

Citation

Mordin, M. M., Clark, M., Siersma, C. A., Copley-Merriman, K., & Gnanasakthy, A. (2009, May). Impact Of The FDA Draft Guidance on Patient Reported Outcomes (PRO) Label Claims for Approved Drug Products in the US: Has It Made a Difference?. Presented at ISPOR 14th Annual International Meeting, .

Abstract